A. Medina

Metastatic Bladder Cancer: Second-Line Treatment and Recommendations of the Genitourinary Tumor Division of the Galician Oncologic Society (SOG-GU)

Jorge García, L. Santomé, U. Anido, 2016, Current Oncology Reports.

Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer.

E. Scarpi, B. Mellado, V. Conteduca, 2019, European journal of cancer.

Association Between Second Progression-free Survival (PFS2) and Overall Survival in Metastatic Castration-resistant Prostate Cancer.

A. Medina, A. Rodriguez-Vida, F. Zambrana, 2020, European urology.

Results of treatment in locally advanced carcinoma of the endometrium.

W. Sakr, V. Ratanatharathorn, A. Medina, 1990, Acta oncologica.

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer

E. Scarpi, B. Mellado, V. Conteduca, 2019, European urology.

PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer.

E. Gallardo, P. Lapunzina, C. Pritchard, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Docetaxel in prostate cancer: a familiar face as the new standard in a hormone-sensitive setting

A. Medina, E. Grande, P. Maroto, 2017, Therapeutic advances in medical oncology.

A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN)

J. Bellmunt, M. Los, R. de Wit, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II trial of durvalumab plus tremelimumab with concurrent radiotherapy (RT) in patients (pts) with localized muscle invasive bladder cancer (MIBC) treated with a selective bladder preservation approach: IMMUNOPRESERVE-SOGUG trial.

O. Etxaniz, A. Medina, S. Villà, 2021 .